Evropska unija - slovenščina - EMA (European Medicines Agency)

biomarin international limited - vosoritide - achondroplasia - zdravila za zdravljenje bolezni kosti - voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. the diagnosis of achondroplasia should be confirmed by appropriate genetic testing.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ha seva b/phuket/3073/2013, divji tip, podoben sevu b/phuket/3073/2013; ha seva b/washington/02/2019, divji tip, podoben sevu b/washington/02/2019; ha seva a/victoria/2570/2019, ivr-215, podoben sevu a/victoria/2570/2019 (h1n1)p; ha seva ivr-224 (iz seva a/cambodia/e0826360/2020, podoben sevu a/cambodia/e0826 - suspenzija za injiciranje v napolnjeni injekcijski brizgi - ha seva b/phuket/3073/2013, divji tip, podoben sevu b/phuket/3073/2013 15 µg / 1 brizga  ha seva b/washington/02/2019, divji tip, podoben sevu b/washington/02/201915 µg / 1 brizga  ha seva a/victoria/2570/2019, ivr-215, podoben sevu a/victoria/2570/2019 (h1n1)p15 µg / 1 brizga  ha seva ivr-224 (iz seva a/cambodia/e0826360/2020, podoben sevu a/cambodia/e082615 µg / 1 brizga; ha seva b/washington/02/2019, divji tip, podoben sevu b/washington/02/2019 15 µg / 1 brizga  ha seva a/victoria/2570/2019, ivr-215, podoben sevu a/victoria/2570/2019 (h1n1)p15 µg / 1 brizga  ha seva ivr-224 (iz seva a/cambodia/e0826360/2020, podoben sevu a/cambodia/e082615 µg / 1 brizga; ha seva a/victoria/2570/2019, ivr-215, podoben sevu a/victoria/2570/2019 (h1n1)p 15 µg / 1 brizga  ha seva ivr-224 (iz seva a/cambodia/e0826360/2020, podoben sevu a/cambodia/e082615 µg / 1 brizga; ha seva ivr-224 (iz seva a/cambodia/e0826360/2020, podoben sevu a/cambodia/e0826 - cepivo proti gripi, z delci virusov ali s površinskimi antigeni, inaktivirano

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ha seva b/phuket/3073/2013, divji tip, podoben sevu b/phuket/3073/2013; ha seva b/washington/02/2019, divji tip, podoben sevu b/washington/02/2019; ha seva a/victoria/2570/2019, ivr-215, podoben sevu a/victoria/2570/2019 (h1n1)p; ha seva ivr-224 (iz seva a/cambodia/e0826360/2020, podoben sevu a/cambodia/e0826 - suspenzija za injiciranje v napolnjeni injekcijski brizgi - ha seva b/phuket/3073/2013, divji tip, podoben sevu b/phuket/3073/2013 15 µg / 1 brizga  ha seva b/washington/02/2019, divji tip, podoben sevu b/washington/02/201915 µg / 1 brizga  ha seva a/victoria/2570/2019, ivr-215, podoben sevu a/victoria/2570/2019 (h1n1)p15 µg / 1 brizga  ha seva ivr-224 (iz seva a/cambodia/e0826360/2020, podoben sevu a/cambodia/e082615 µg / 1 brizga; ha seva b/washington/02/2019, divji tip, podoben sevu b/washington/02/2019 15 µg / 1 brizga  ha seva a/victoria/2570/2019, ivr-215, podoben sevu a/victoria/2570/2019 (h1n1)p15 µg / 1 brizga  ha seva ivr-224 (iz seva a/cambodia/e0826360/2020, podoben sevu a/cambodia/e082615 µg / 1 brizga; ha seva a/victoria/2570/2019, ivr-215, podoben sevu a/victoria/2570/2019 (h1n1)p 15 µg / 1 brizga  ha seva ivr-224 (iz seva a/cambodia/e0826360/2020, podoben sevu a/cambodia/e082615 µg / 1 brizga; ha seva ivr-224 (iz seva a/cambodia/e0826360/2020, podoben sevu a/cambodia/e0826 - cepivo proti gripi, z delci virusov ali s površinskimi antigeni, inaktivirano

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

kaspofungin - prašek za koncentrat za raztopino za infundiranje - kaspofungin 70 mg / 1 viala - kaspofungin

Evropska unija - slovenščina - EMA (European Medicines Agency)

gilead sciences ireland uc - sacituzumab govitecan - breast neoplasms; triple negative breast neoplasms - antineoplastična sredstva - trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mtnbc) who have received two or more prior systemic therapies, including at least one of them for advanced disease.

Evropska unija - slovenščina - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - karcinom, pljučni pljuč - antineoplastična sredstva - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Evropska unija - slovenščina - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - pegcetacoplan - hemoglobinurija, paroksizmal - imunosupresivi - aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh) who are anaemic after treatment with a c5 inhibitor for at least 3 months.

Evropska unija - slovenščina - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - lupus erythematosus, sistemski - imunosupresivi - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.

Evropska unija - slovenščina - EMA (European Medicines Agency)

swedish orphan biovitrum ab - loncastuximab tesirine - lymphoma, large b-cell, diffuse; lymphoma, b-cell - antineoplastična sredstva - zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl), after two or more lines of systemic therapy.

Evropska unija - slovenščina - EMA (European Medicines Agency)

neuraxpharm pharmaceuticals s.l. - ublituximab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.